Alector price target lowered to $5 from $16 at BTIG

BTIG lowered the firm’s price target on Alector (ALEC) to $5 from $16 and keeps a Buy rating on the shares. The TREM2 activation had little effect in Alzheimer’s disease, not a positive for the world of genome-wide association studies-driven medicine, the analyst tells investors in a research note, adding that the mechanism of ARIA-E may also need to be revisited.